Home / Research library / Cagrilintide
Cagrilintide: molecular data, studies & sources
Cagrilintide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C194H312N54O59S2
- Molecular weight (MW)
- 4409 g/mol
- PubChem compound ID
- 171397054
- Record title
- Cagrilintide
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 171397054 · retrieved 2026-09-21

Chemical identifiers and source data
- IUPAC name
- 20-[[(1S)-4-[[(2S)-6-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R,3S)-1-[[(2R)-4-amino-1-[[(2R)-1-[[2-[[(2R)-1-[[(2R)-4-amino-1-[[(2R,3S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-16-(2-amino-2-oxoethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
- InChIKey
- LDERDVMBIYGIOI-IZVMHKDJSA-N
- SMILES
- CC[C@H](C)[C@@H](C(=O)N[C@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](CC(=O)N)C(=O)N[C@H](C(C)C)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](CC(=O)N)C(=O)N[C@H]([C@H](C)O)C(=O)N3CCC[C@@H]3C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O
Human and clinical studies
Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.
- Human study · PubMed trial index
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT, Blüher M, Osorto Contreras CK et al. · The New England journal of medicine · 2025
PMID 40544433 · DOI: 10.1056/NEJMoa2502081
- Human study · PubMed trial index
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Davies MJ, Bajaj HS, Broholm C et al. · The New England journal of medicine · 2025
PMID 40544432 · DOI: 10.1056/NEJMoa2502082
- Human study · PubMed trial index
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW, Erichsen L, Francisco AM et al. · Lancet (London, England) · 2021
PMID 34798060 · DOI: 10.1016/S0140-6736(21)01751-7
- Human study · PubMed trial index
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Frias JP, Deenadayalan S, Erichsen L et al. · Lancet (London, England) · 2023
PMID 37364590 · DOI: 10.1016/S0140-6736(23)01163-7
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Research publication · design requires review
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.
D'Ascanio AM, Mullally JA, Frishman WH et al. · Cardiology in review · 2024 Jan-Feb 01
PMID 36883831 · DOI: 10.1097/CRD.0000000000000513
Cagrilintide supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Compare all Cagrilintide sizes, forms and supplier prices →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| American PeptidesUSD | 10mg Vial1 recorded offers | 10mg Vial · $170.00Checked Sep 21, 2026Supplier listing |
| Modified AminosUSD | 10mg Vial1 recorded offers | 10mg Vial · $69.99Checked Sep 16, 2026Supplier listing |
| Amino ClubUSD | 10mg Vial1 recorded offers | 10mg Vial · $69.99Checked Sep 16, 2026Supplier listing |
| Amino USAUSD | 10mg Vial · 5mg Vial2 recorded offers | 10mg Vial · $91.80Checked Sep 16, 2026Supplier listing |
| Cenexa LabsUSD | 10mg Vial1 recorded offers | 10mg Vial · $159.99Checked Sep 16, 2026Supplier listing |
| Direct PeptidesUSD | 10mg Vial1 recorded offers | 10mg Vial · $109.00Checked Sep 16, 2026Supplier listing |
Reference sources & further reading
- PubChem compound record 171397054 — chemical identity and structure.
- Wikipedia: Cagrilintide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Liraglutide
C172H265N43O51
3751 g/mol · PubChem CID 16134956
7 selected publications · 5 human study records
Mazdutide
C207H317N45O65
4476 g/mol · PubChem CID 167312357
6 selected publications · 5 human study records
Retatrutide
C221H342N46O68
4731 g/mol · PubChem CID 171390338
8 selected publications · 6 human study records
Semaglutide
C187H291N45O59
4114 g/mol · PubChem CID 56843331
8 selected publications · 5 human study records
Survodutide
C192H289N47O61
4232 g/mol · PubChem CID 168429725
5 selected publications · 5 human study records
Tirzepatide
C225H348N48O68
4813 g/mol · PubChem CID 156588324
8 selected publications · 7 human study records